Amyotrophic Lateral Sclerosis & Chronic Lymphocytic Leukemia Market Epidemiology Forecast to 2023 Reports Available at RnRMarketResearch.com
Dallas, Texas (PRWEB) May 14, 2014 -- EpiCast Report: Amyotrophic Lateral Sclerosis – Epidemiology Forecast to 2023
Amyotrophic lateral sclerosis (ALS), often referred to as “Lou Gehrig’s Disease,” is a rare, but fatal, progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord. ALS severely impacts physical functioning and initially presents with muscle twitching, weakness in an arm or leg, or with slurring of speech. Eventually, people with ALS lose their ability to control the muscles needed to move, speak, eat, and breathe, which ultimately leads to death. The progressively degenerative course of the condition is a great burden for both patients and caregivers, as well as for society.
Epidemiologists forecast that the diagnosed prevalent cases of ALS in the 7MM will grow by 13.5% over the next decade, from 32,698 diagnosed prevalent cases in 2013 to 37,122 diagnosed prevalent cases in 2023. Throughout the forecast period, the US will have the highest numbers of diagnosed prevalent cases of ALS, followed by Japan.
Complete report of Amyotrophic Lateral Sclerosis Market available @ http://www.rnrmarketresearch.com/epicast-report-amyotrophic-lateral-sclerosis-epidemiology-forecast-to-2023-market-report.html .
To develop the epidemiological forecast for the diagnosed prevalent cases of ALS in the 7MM, Epidemiologists obtained the diagnosed prevalence data for ALS from peer-reviewed journals and population-based studies in the respective markets and used a consistent methodology to ensure comparability of the results. A major strength of epidemiological analysis is the use of country-specific studies that provided the diagnosed prevalence of ALS using uniform diagnostic criteria based on the El Escorial criteria or the International Classification of Diseases, Ninth Revision (ICD-9), criteria (ICD-9 code for ALS = 335.2), to allow for a meaningful comparison of the diagnosed prevalent cases of ALS in these markets. Furthermore, the diagnosed prevalent cases of ALS in each of the 7MM were further segmented by age and sex in order to provide a more detailed analysis of the patient population. Order purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=173921 .
The Amyotrophic lateral sclerosis (ALS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for ALS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of ALS segmented by age (=40 years) and sex in these markets.
EpiCast Report: Chronic Lymphocytic Leukemia – Epidemiology Forecast to 2023
Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection.
CLL is the most common form of leukemia in the western world, with an average annual incidence of 5.0 per 100,000 populations in people of all ages. CLL is primarily a disease of the elderly population, with less than 10% of the cases below 40 years of age.
Epidemiologists forecast an increase in the diagnosed incident cases of CLL in the 6MM, from 37,795 diagnosed incident cases in 2013 to 45,683 diagnosed incident cases in 2023, with an annual growth rate (AGR) of 2.09% during the forecast period. The 5-year diagnosed prevalent cases of CLL in the 6MM increased from 150,800 diagnosed prevalent cases in 2013 to 183,165 diagnosed prevalent cases in 2023, with an AGR of 2.15% during the forecast period.
Complete report of Chronic Lymphocytic Leukemia Market available @ http://www.rnrmarketresearch.com/epicast-report-chronic-lymphocytic-leukemia-epidemiology-forecast-to-2023-market-report.html .
Epidemiological forecast for the diagnosed incident and 5-year diagnosed prevalent cases of CLL in the 6MM is supported by ageand sex-specific data for incidence and 1to 5-year relative survival data used for the 5-year diagnosed prevalent cases forecast are supported by country-specific, population-based studies that are nationally representative of the entire population in the respective markets. The diagnosed incident cases of CLL in each of the 6MM were further segmented by Rai stage at diagnosis to provide a more detailed analysis of the patient population, as Rai stage at diagnosis is an important factor for predicting the prognosis and treatment modalities for CLL at different stages. Order purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=173920 .
The Chronic lymphocytic leukemia (CLL) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for CLL in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). In addition, the report also includes a 10-year epidemiological forecast of the diagnosed incident cases of CLL segmented by age (beginning at 40 years and ending at 80 years and older) and sex. Epidemiologists also forecast the 5-year diagnosed prevalent cases of CLL in the 6MM. additionally; the report provides CLL diagnosed incident cases segmented by Rai stage at diagnosis for the 6MM.
Explore more reports on the Therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Priyank Tiwari, RnRMarketResearch.com, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article